The groups will work together to enhance Africa's vaccine infrastructure, with CEPI committing up to $145 million to ...

The US Food and Drug Administration yesterday approved Bristol Myers Squibb’s (NYSE: BMY) Breyanzi (lisocabtagene maraleucel ...

Privately-held UK clinical-stage firm Soterios Pharma has announced positive multi-dose Phase II trial evaluating STS-01 as ...

Biotech firm Moderna (Nasdaq: MRNA) has won US Food and Drug Administration (FDA) approval for mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 ...

Swiss pharma giant Novartis (NOVN: VX) today announced new data that confirm the long-term efficacy and safety of remibrutinib, a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, in ...

The study is comparing the first-in-class Trop-2-directed antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) with chemotherapy, in people with advanced or metastatic bladder cancer ...

If approved, zolbetuximab would be the first CLDN18.2-targeted therapy available in the U.S. for these patients. The BLA was resubmitted following a complete response letter issued by the FDA on ...

Autoimmune diseases specialist Immunovant (Nasdaq: IMVT) has opted to prioritize the development of IMVT-1402 as its lead asset due to its broad potential across a number of indications.

The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) ...

The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab ...

The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, ...

Privately-held UK clinical-stage firm Soterios Pharma has announced positive multi-dose Phase II trial evaluating STS-01 as a treatment for mild/moderate alopecia areata (AA).